[Edaily Reporter Kwon Oh Seok ] Shares of From Bio Co., Ltd.(377220), which resumed trading following a reverse stock split, have hit the daily price limit for two consecutive trading days. News that the company is accelerating the development of a cell therapy for hair loss also appears to be boosting investor sentiment.

According to MP Doctor on the 11th, as of 19 minutes past the hour, From Bio Co., Ltd.’s stock is trading at the daily price limit of 4,325 won, up 29.88% from the previous trading day.
Earlier that day, the company issued a press release stating, “We have completed the GLP general toxicity test for a hair loss cell therapy based on adipose-derived mesenchymal stem cells (ADSCs) and differentiated cells (dADSCs), led by the From Bio Co., Ltd. Comprehensive Technology Research Institute.” The company is currently conducting follow-up preclinical trials, including evaluations of in vivo distribution and tumorigenicity, and is pursuing R&D with the goal of submitting an Investigational New Drug (IND) application in 2027.
This therapy is being developed using dADSCs produced through a proprietary differentiation process applied to adipose-derived mesenchymal stem cells. The company is accumulating a body of evidence by conducting research on the characteristics of the candidate cells and the manufacturing process, while simultaneously carrying out the nonclinical safety evaluations required for entry into the clinical development phase in a phased manner.
From Bio Co., Ltd. is also concurrently establishing a foundation for the stable manufacturing and quality control of cell therapies. From Bio Co., Ltd. has established a Master Cell Bank (MCB) and a Working Cell Bank (WCB) and has secured 18-month long-term stability data to date. In addition, the company is continuing research to enhance the reproducibility and quality consistency of its manufacturing process, which encompasses cell culture, differentiation, and cryopreservation.
In its existing health functional food business, the company is continuously building R&D capabilities based on ingredients individually approved by the Ministry of Food and Drug Safety (MFDS). From Bio Co., Ltd.’s strategy is to diversify its business portfolio and strengthen its foundation for mid- to long-term growth by fostering both its existing health functional food business and its new biotech business in tandem.